Back to Search
Start Over
Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer
- Source :
- © Inflammatory Bowel Diseases, 2016, vol. 22, núm. 1, p. 28-41, Articles publicats (D-B), DUGiDocs – Universitat de Girona, instname, Recercat. Dipósit de la Recerca de Catalunya
- Publication Year :
- 2018
- Publisher :
- Wolters Kluwer, 2018.
-
Abstract
- Background: Faecalibacterium prausnitzii comprises 2 phylogroups, whose abundance in healthy and diseased gut and in conjunction with Escherichia coli has not yet been studied. This work aims to determine the contribution of F. prausnitzii phylogroups I and II in intestinal disease and to assess their potential diagnostic usefulness as biomarkers for gut diseases. Methods: Total F. prausnitzii, its phylogroups, and E. coli loads were determined by quantitative polymerase chain reaction targeting the 16S rRNA gene on biopsies from 31 healthy controls (H), 45 patients with Crohn's disease (CD), 25 patients with ulcerative colitis, 10 patients with irritable bowel syndrome, and 20 patients with colorectal cancer. Data were normalized to total bacterial counts and analyzed according to patients' disease location and clinical characteristics. Results: Lower levels of both total F. prausnitzii and phylogroup I were found in subjects with CD, ulcerative colitis, and colorectal cancer (P < 0.001) compared with H subjects. Phylogroup I load was a better biomarker than total F. prausnitzii to discriminate subjects with gut disorders from H. Phylogroup II depletion was observed only in patients with CD (P < 0.001) and can be potentially applied to differentiate ulcerative pancolitis from colonic CD. No statistically significant correlation between E. coli and any of the 2 F. prausnitzii phylogroups was found in any group of patients or by inflammatory bowel disease location. Phylogroup I was lower in active patients with CD, whereas those CD with intestinal resection showed a reduction in phylogroup II. Treatments with mesalazine and immunosuppressants did not result in the recovery of F. prausnitzii phylogroups abundance. Conclusions: F. prausnitzii phylogroup I was depleted in CD, ulcerative colitis, and colorectal cancer, whereas phylogroup II was specifically reduced in CD. Quantification of F. prausnitzii phylogroups and E. coli may help to identify gut disorders and to classify inflammatory bowel disease location.
- Subjects :
- Male
0301 basic medicine
Faecalibacterium prausnitzii
Colon (Anatomy) -- Cancer
Crohn, Malaltia de
Gastroenterology
Inflammatory bowel disease
Bacteris
Cohort Studies
chemistry.chemical_compound
Intestinal mucosa
RNA, Ribosomal, 16S
Prevalence
Immunology and Allergy
Medicine
Intestinal Mucosa
Phylogeny
Irritable bowel syndrome
Intestins -- Inflamació
Rectum -- Cancer
Crohn's disease
biology
Middle Aged
Prognosis
Ulcerative colitis
Còlon -- Càncer
Female
medicine.symptom
Colorectal Neoplasms
Adult
DNA, Bacterial
medicine.medical_specialty
Pancolitis
Inflammatory bowel diseases
Gram-Positive Bacteria
Real-Time Polymerase Chain Reaction
03 medical and health sciences
Mesalazine
Internal medicine
Humans
Gram-Positive Bacterial Infections
Bacteria
business.industry
Inflammatory Bowel Diseases
medicine.disease
biology.organism_classification
030104 developmental biology
chemistry
Case-Control Studies
Immunology
Recte -- Càncer
business
Follow-Up Studies
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- © Inflammatory Bowel Diseases, 2016, vol. 22, núm. 1, p. 28-41, Articles publicats (D-B), DUGiDocs – Universitat de Girona, instname, Recercat. Dipósit de la Recerca de Catalunya
- Accession number :
- edsair.doi.dedup.....ba6f73c5042ddbdcefbe561c6fde1f72